KetoNiFast: Cyclic Enteral Daytime Feeding With Ketogenic Nighttime Fasting

Launched by UNIVERSITY HOSPITAL OF COLOGNE · Jul 30, 2024

Keywords

ClinConnect Summary

The KetoNiFast trial is studying a new way to provide nutrition to patients in the Intensive Care Unit (ICU). This study looks at the effects of feeding patients during the day while allowing them to fast at night. The idea is that fasting at night, which is a natural process for our bodies, may help with recovery by supporting healing and reducing inflammation. Instead of continuous feeding, participants will receive nutrition for 12 hours followed by a 12-hour fasting period, combined with special supplements called ketone salts.

To be eligible for the trial, patients must be admitted to the ICU and agree to participate by providing written consent. However, certain health conditions could exclude them, such as severe liver or kidney issues, pregnancy, or severe metabolic disorders. Participants can expect to follow this new feeding schedule while their health is monitored, and the results may help improve nutrition strategies for critically ill patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • written informed consent to participate in this study
• • admission to ICU
• • enteral nutrition
• Exclusion Criteria:
• • Severe liver dysfunction / liver failure (Child Pugh \>7 points / category B)
• • Severe kidney dysfunction (KDIGO stage 3)
• • Total pancreatectomy / insulin dependent diabetes mellitus (IDDM)
• • Pregnancy / lactation
• • Hemoglobin concentration \< 80g/l
• • Severe metabolic disorders / severe autoimmune diseases
• • Refractory metabolic or respiratory acidosis
• • Dysfunction of mitochondrial transport of fatty acids
• • Dysfunction of oxidation of fatty acids
• • Dysfunction of gluconeogenesis, production and reduction of ketones
• • Intermittent Porphyria
• • Severe cardiac arrhythmias / cardiomyopathy
• • Contraindication against enteral nutrition
• • Lack of informed consent